Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: In vitro and in vivo studies

Journal of Pharmaceutical Sciences

Volumn 99, Issue 8, 2010, Pages 3552-3560

  Zhao, Lingyun ^a,b   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Anticancer drugs; Cancer nanotechnology; Chemotherapeutic engineering; Nanomedicine; Oral bioavailability

Indexed keywords

ALPHA TOCOPHEROL; EMULSIFYING AGENT; NANOPARTICLE; PACLITAXEL; POLYMER; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DRUG CARRIER; EXCIPIENT; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOAVAILABILITY; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SOLVENT EXTRACTION; ANALOGS AND DERIVATIVES; ANIMAL; BIODEGRADABLE IMPLANT; CHEMISTRY; ELECTROCHEMISTRY; LIGHT; MEDICINAL CHEMISTRY; RADIATION SCATTERING; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; ELECTROCHEMISTRY; EXCIPIENTS; HUMANS; LACTIC ACID; LIGHT; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SCATTERING, RADIATION; VITAMIN E;

EID: 77955108815     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22113     Document Type: Article

References (35)

1. Bromberg L. 2008. Polymeric micelles in oral chemotherapy. J Controlled Res 128:99-112.
2. Terwogt JMM, Schellens JHM, Huinink WWT, Beijnen JH. 1999. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treatment Rev 25:83-101.
3. Wahl AF, Donaldson KL, Fairchild D, Lee FYF, Foster SA, Demers W, Galloway DA. 1996. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72-79.
4. Zhao LY, Feng SS. 2004. Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J Pharm Sci 93:86-98.
5. Malingre MM, Beijnen JH, Schellens JHM. 2001. Oral delivery of taxanes. Invest New Drugs 19:155-162.
6. Terwogt JMM, Malingre MM, Beijnen JH, Huinink WW, Rosing BH, Koopman FJ, Tellingen O, Swart M, Schellens JHM. 1999. Coadministration of oral cyclosporine A enalbels oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384.
7. Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky RK. 2000. Oral paclitaxel and concurrent cyclosporine A: Targeting clinincally relevant systemic exposure to paclitaxel. Clin Cancer Res 6:3459-3468.
8. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. 2002. P-glycoproteim inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 49:322-328.
9. Jamois C, Comets E, Mentre F, Marion S, Farinotti R, Faivre LB. 2005. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. Cancer Chemother Pharmacol 55:61-71. (Pubitemid 40064497)
10. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Huinink WWB, Schellens JHM. 2001. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84:42-47.
11. Choi JK, Shin SC. 2005. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int J Pharm 292:149-156. (Pubitemid 40255796)
12. Choi JS, Jo BW, Kim YC. 2004. Enhanced paclitaxel bioavailability after oral administration of palcitaxle or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57:313-318.
13. Woo JS, Lee CH, Shim CK, Hwang SJ. 2003. Enhanced oral bioavailability of paclitaxel by coadministraiton of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24-30.
14. Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A. 2008. Oral bioavailability of novel paclitaxel formulation (Genetaxyl) administered with cyclosporine A in cancer. Anti-Cancer Drugs 19: 275-281.
15. Feng SS. 2004. Nanoparticles of biodegradable polymers for new concept chemotherapy. Expert Rev Med Dev 1:115-125. (Pubitemid 40220423)
16. Feng SS, Chien S. 2003. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy cancer and other diseases. Chem Eng Sci 58:4087-4114.
17. Prokop A, Davidsan JM. 2008. Nanovehicular intracellular delivery systems. J Pharm Sci 97:3518-3590.
18. Feng SS, Zhao LY, Zhang ZP, Gajadhar B, Khin YW, Dong YC, Chien S. 2007. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem Eng Sci 62:6641-6648.
19. Traber MG, Schiano TD, Steephen AC, Kayden HJ, Shike M. 1994. Efficacy of water-soluble vitamin-E in the treatment of vitamin-E malabsorption in shrot bowel syndrome. Am J Clin Nutr 59:1270-1274. (Pubitemid 24978991)
20. Dong YC, Feng SS. 2004. Methoxy poly(ethylene glycol)-poly-(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drug. Biomaterials 5:2843-2849.
21. Dong YC, Feng SS. 2005. Poly(D,L-Lactide-co-glycolide)/montnorillonite nanoparticles for oral delivery of anti-cancer drugs. Biomaterials 26:6068-6076.
22. Win KY, Feng SS. 2005. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713-2722.
23. Win KY, Feng SS. 2006. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolid acid) nanoparticles for paclitaxel formulation. Biomaterials 27:2285-2291.
24. Feng SS. 2008. Snapshot: Nanoparticles of biodegradable polymers for cancer treatment. Biomaterials 29:4146-4147.
25. Mu L, Feng SS. 2003. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Controlled Release 86:33-48.
26. Pan J, Feng SS. 2008. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29:2663-2672.
27. Bogman K, Erne-Brand F, Alsenz J, Drewe J. 2003. The role of surfactants in reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 92:1250-1261. (Pubitemid 36676470)
28. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J. 2005. P-glycoprotein and surfactants: Effects on intestined talindol absorption. Clin Pharmacol Ther 77:24-32.
29. Ho PY, Yeh TK, Yao HT, Lin HL, Wu HY, Lo YK, Chang YW, Chiang TH, Wu SHW, Chao YS, Chen CT. 2008. Enhanced oral bioavailability of paclitaxel by D-a-tocopherul polyethelene glycol 400 succinate in mice. Int J Pharm 359:174-181.
30. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. 2003. Intracellular uptake of anionic superaramagnetic nanoparticles as a function of their surface coating. Biomaterials 24:1001-1011.
31. Peltier S, Oger JM, Lagarce F, Couet W, Benoit JP. 2006. Enhanced oral paclitaxel bioavailability after administration of palcitaxle-loaded lipid nanocapsules. Pharm Res 6:1243-1250.
32. Lee SH, Zhang ZP, Feng SS. 2007. Nanoparticles of poly-(lactide)- tocopheryl polyethene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 28:2041-2050.
33. Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K. 2007. Hydrotropic polymeric micelles for enhanced paclitaxel solubility: In vitro and in vivo characterization. Biomacromolecules 8:202-208.
34. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, Kuo MS, Hageman MJ. 2003. Development of a supersaturable SEDDS (S-SEDDS) formulation of palcitaxel with improved oral bioavailability. J Pharm Sci 92:2386-2398.
35. Varma MVS, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.